{"id":39537,"date":"2026-08-03T14:03:21","date_gmt":"2026-08-03T12:03:21","guid":{"rendered":"https:\/\/ggba.swiss\/ab2-bio-receives-usd-30-million-as-nippon-shinyaku-takes-up-us-rights\/"},"modified":"2026-08-03T14:05:46","modified_gmt":"2026-08-03T12:05:46","slug":"ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/","title":{"rendered":"AB2 Bio re\u00e7oit USD 30 millions de Nippon Shinyaku"},"content":{"rendered":"\n

AB2 Bio<\/a>, bas\u00e9e \u00e0 l’EPFL Innovation Park<\/a> \u00e0 Lausanne, a re\u00e7u un paiement de USD 30 millions apr\u00e8s que Nippon Shinyaku<\/a> a exerc\u00e9 son option de commercialisation du Tadekinig alfa aux \u00c9tats-Unis. L’entreprise peut pr\u00e9tendre \u00e0 jusqu’\u00e0 USD 100 millions de paiements d’\u00e9tape li\u00e9s au d\u00e9veloppement et \u00e0 jusqu’\u00e0 USD 500 millions de paiements d’\u00e9tape commerciaux et de redevances.<\/p>\n\n\n\n

Fond\u00e9e en 2010, AB2 Bio d\u00e9veloppe des th\u00e9rapies contre les syndromes hyperinflammatoires li\u00e9s \u00e0 l’interleukine-18 (IL-18). Le syndrome hyperinflammatoire monog\u00e9nique primaire li\u00e9 \u00e0 l’IL-18, caus\u00e9 par des mutations des g\u00e8nes NLRC4 et XIAP, entra\u00eene une \u00e9l\u00e9vation marqu\u00e9e des taux d’IL-18 libre, une prot\u00e9ine de signalisation qui alimente l’inflammation syst\u00e9mique. Cette affection touche principalement les nourrissons et les jeunes enfants, peut \u00e9voluer rapidement vers une d\u00e9faillance multivisc\u00e9rale et ne dispose d’aucun traitement approuv\u00e9, la prise en charge standard visant les sympt\u00f4mes plut\u00f4t que le m\u00e9canisme sous-jacent.<\/p>\n\n\n\n

Le Tadekinig alfa est une version recombinante de la prot\u00e9ine humaine de liaison \u00e0 l’IL-18, l’inhibiteur naturel de l’IL-18, con\u00e7ue pour neutraliser l’exc\u00e8s d’IL-18 libre et r\u00e9tablir l’\u00e9quilibre entre les deux. L’entreprise a achev\u00e9 son programme de phase 3 dans l’indication principale et fait \u00e9tat d’une preuve de concept clinique dans trois autres maladies orphelines. Le candidat b\u00e9n\u00e9ficie du statut de m\u00e9dicament orphelin aux \u00c9tats-Unis et en Europe, ainsi que des d\u00e9signations \u00ab breakthrough therapy \u00bb et maladie p\u00e9diatrique rare de la Food and Drug Administration am\u00e9ricaine.<\/p>\n\n\n\n

Les deux entreprises avaient sign\u00e9 un accord d’option et de licence en janvier 2025, au titre duquel AB2 Bio avait per\u00e7u USD 6 millions. Nippon Shinyaku d\u00e9tient d\u00e9sormais les droits exclusifs de commercialisation aux \u00c9tats-Unis pour l’indication conc\u00e9d\u00e9e, tandis qu’AB2 Bio conserve toutes les autres indications aux \u00c9tats-Unis et l’ensemble des indications ailleurs. AB2 Bio continue de piloter la pr\u00e9paration du dossier d’autorisation biologique (BLA) et les autres d\u00e9marches r\u00e9glementaires am\u00e9ricaines, la cl\u00f4ture pouvant n\u00e9cessiter une autorisation au titre du droit antitrust am\u00e9ricain.<\/p>\n","protected":false},"excerpt":{"rendered":"

AB2 Bio a re\u00e7u un paiement de USD 30 millions apr\u00e8s que le groupe pharmaceutique japonais Nippon Shinyaku a exerc\u00e9 son option de commercialisation du Tadekinig alfa aux \u00c9tats-Unis, avec jusqu’\u00e0 USD 600 millions de paiements d’\u00e9tape et de redevances suppl\u00e9mentaires.<\/p>\n","protected":false},"author":6,"featured_media":39534,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1188,1171,1142],"class_list":["post-39537","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-healthcare-fr-2","tag-pharma-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"\nAB2 Bio re\u00e7oit USD 30 millions de Nippon Shinyaku | GGBa<\/title>\n<meta name=\"description\" content=\"AB2 Bio re\u00e7oit un paiement de USD 30 millions apr\u00e8s l'exercice par Nippon Shinyaku de son option sur les droits am\u00e9ricains du Tadekinig alfa.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AB2 Bio re\u00e7oit USD 30 millions de Nippon Shinyaku | GGBa\" \/>\n<meta property=\"og:description\" content=\"AB2 Bio re\u00e7oit un paiement de USD 30 millions apr\u00e8s l'exercice par Nippon Shinyaku de son option sur les droits am\u00e9ricains du Tadekinig alfa.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-03T12:03:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-03T12:05:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/AB2Bio-Conceptual-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"AB2 Bio re\u00e7oit USD 30 millions de Nippon Shinyaku\",\"datePublished\":\"2026-08-03T12:03:21+00:00\",\"dateModified\":\"2026-08-03T12:05:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/\"},\"wordCount\":376,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/AB2Bio-Conceptual-1180x811-1.png\",\"keywords\":[\"Biotech\",\"Financing\",\"Healthcare\",\"Pharma\",\"R&D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/\",\"name\":\"AB2 Bio re\u00e7oit USD 30 millions de Nippon Shinyaku | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/AB2Bio-Conceptual-1180x811-1.png\",\"datePublished\":\"2026-08-03T12:03:21+00:00\",\"dateModified\":\"2026-08-03T12:05:46+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"AB2 Bio re\u00e7oit un paiement de USD 30 millions apr\u00e8s l'exercice par Nippon Shinyaku de son option sur les droits am\u00e9ricains du Tadekinig alfa.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/AB2Bio-Conceptual-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/AB2Bio-Conceptual-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"AB2 Bio d\u00e9veloppe des th\u00e9rapies contre les syndromes hyperinflammatoires li\u00e9s \u00e0 l'interleukine-18, une prot\u00e9ine de signalisation impliqu\u00e9e dans l'inflammation syst\u00e9mique.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AB2 Bio re\u00e7oit USD 30 millions de Nippon Shinyaku\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AB2 Bio re\u00e7oit USD 30 millions de Nippon Shinyaku | GGBa","description":"AB2 Bio re\u00e7oit un paiement de USD 30 millions apr\u00e8s l'exercice par Nippon Shinyaku de son option sur les droits am\u00e9ricains du Tadekinig alfa.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/","og_locale":"fr_FR","og_type":"article","og_title":"AB2 Bio re\u00e7oit USD 30 millions de Nippon Shinyaku | GGBa","og_description":"AB2 Bio re\u00e7oit un paiement de USD 30 millions apr\u00e8s l'exercice par Nippon Shinyaku de son option sur les droits am\u00e9ricains du Tadekinig alfa.","og_url":"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-08-03T12:03:21+00:00","article_modified_time":"2026-08-03T12:05:46+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/AB2Bio-Conceptual-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"AB2 Bio re\u00e7oit USD 30 millions de Nippon Shinyaku","datePublished":"2026-08-03T12:03:21+00:00","dateModified":"2026-08-03T12:05:46+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/"},"wordCount":376,"image":{"@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/AB2Bio-Conceptual-1180x811-1.png","keywords":["Biotech","Financing","Healthcare","Pharma","R&D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/","url":"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/","name":"AB2 Bio re\u00e7oit USD 30 millions de Nippon Shinyaku | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/AB2Bio-Conceptual-1180x811-1.png","datePublished":"2026-08-03T12:03:21+00:00","dateModified":"2026-08-03T12:05:46+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"AB2 Bio re\u00e7oit un paiement de USD 30 millions apr\u00e8s l'exercice par Nippon Shinyaku de son option sur les droits am\u00e9ricains du Tadekinig alfa.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/AB2Bio-Conceptual-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/AB2Bio-Conceptual-1180x811-1.png","width":1180,"height":811,"caption":"AB2 Bio d\u00e9veloppe des th\u00e9rapies contre les syndromes hyperinflammatoires li\u00e9s \u00e0 l'interleukine-18, une prot\u00e9ine de signalisation impliqu\u00e9e dans l'inflammation syst\u00e9mique."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/ab2-bio-recoit-usd-30-millions-de-nippon-shinyaku\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"AB2 Bio re\u00e7oit USD 30 millions de Nippon Shinyaku"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=39537"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39537\/revisions"}],"predecessor-version":[{"id":39539,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39537\/revisions\/39539"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/39534"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=39537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=39537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=39537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}